Embed Size (px)
Citation preview
DECISION RESOURCESKnowledge, Experience, Insight
PatientBase™…..(Decision Resources’ Customizable
Epidemiology Database)
© Decision Resources, Inc., 2005
2
Company Confidential
DECISION RESOURCES >
PatientBase™
Features
Methodology
Demonstration
Applications / Uses
Appendix
DECISION RESOURCESKnowledge, Experience, Insight
PatientBase™
4
Company Confidential
DECISION RESOURCES >
What is PatientBase™> Online database of 103 diseases and 153 indications> Therapeutic Coverage
> Geographic Focus United States Japan France, Germany, Italy, Spain and United Kingdom
> Frequency of Outputs Released quarterly with most indications updated annually
> Created, analyzed and validated by DR’s well-credentialed Epidemiology staff
1. Cancer 4. Immune & Inflammatory2. Cardiovascular 5. Infectious3. CNS 6. High Interest Diseases like Obesity,
Osteoporosis, Erectile Dysfunction etc.
5
Company Confidential
DECISION RESOURCES >
PatientBase™ Features
> 10 year forecast – 2004 to 2014 Prevalent cases / Incident cases Diagnosed Drug treated Five-year age cohorts By gender Types of sub-population (Co-morbidity, Severity,
Seasonality etc.) Corresponding UN population
> Data portability into Excel> Complete access to Sources & Methodology behind
the data
6
Company Confidential
DECISION RESOURCES >
PatientBase™ Development Methodology> Epidemiologists conduct exhaustive secondary literature
searches Several hundred studies are reviewed for each indication If appropriate, analyses of primary data sources are conducted
> Epidemiologists choose the best country-specific population-based studies Size and representativeness of subject population and rigor of
case ascertainment methods
> Academic epidemiological methods are applied in conducting analyses to determine methodology
> Age- and gender-specific incidence or prevalence is applied to age- and gender-specific United Nations population estimates For each country to reflect influence of demographic changes over
time on patient populations
7
Company Confidential
DECISION RESOURCES >
Epidemiology Data SourcesDR’s expert epidemiologists consult primary data sources, team with expert reviewers, and review hundreds of secondary data sources for estimating
incidence/prevalence trends
ECABundes-Gesundheitssurvey 98
DECISION RESOURCESKnowledge, Experience, Insight
PatientBase™ - Demonstration
9
Company Confidential
DECISION RESOURCES >
PatientBase™ – Demonstration (First Page)
Begin by selectingan indication (Up to 16 indications at one time)
Click to go to the Epi Query page
10
Company Confidential
DECISION RESOURCES >
PatientBase™ – Demonstration (Epi Query)
11
Company Confidential
DECISION RESOURCES >
PatientBase™ – Demonstration (Epi Query)Step 1
12
Company Confidential
DECISION RESOURCES >
PatientBase™ – Demonstration (Epi Query)Step 2 Subpopulation is the distribution of
Prevalent/Incident cases specific to an Indication
provided for more than half of all diseases and conditions
Co-morbidity
Severity
Laboratory measure
Seasonality
Etiology
Pathogen type
Infection site
Treatment type
13
Company Confidential
DECISION RESOURCES >
PatientBase™ – Demonstration (Epi Query)Step 3
Prevalent cases: all patients with the disease/condition at a point in time
Incident cases: all patients newly diagnosed with the disease/condition
Drug-treated cases: all diagnosed patients who are receiving pharmacotherapy
Corresponding U.N. population data: the total number of United Nations-estimated people in the population that corresponds to the cases of people with the disease or condition
14
Company Confidential
DECISION RESOURCES >
PatientBase™ – Demonstration (Epi Query)Step 4
•Regional total: total regional patient populations (United States, Europe, Japan)
•Country total: total country patient populations (United States, France, Germany, Italy, Spain, the United Kingdom, and Japan)
•Country and gender detail: breakout of country-specific patient populations by male and female
•Country, gender, and age detail: breakout of country-specific patient populations by male and female and by 5-year age breakouts
15
Company Confidential
DECISION RESOURCES >
PatientBase™ – Demonstration (Epi Query)Step 5
> Formatted table: data are presented in attractive table for ease of use and presentation
> Raw data spreadsheet: data are presented in raw table which is easiest to manipulate when exported to Excel
> Both formats can be exported to Excel for further manipulation
> Forecast period: forecast is presented in 5 year increments 2004 2009 2014
> Client can choose to view annualized forecasts through 2014 or forecasts of individual years
16
Company Confidential
DECISION RESOURCES >
PatientBase™ – Demonstration (Epi Results)
17
Company Confidential
DECISION RESOURCES >
PatientBase™ – Demonstration (Epi Results)Tool Bar
•Methodology: thorough and transparent discussions of overall and country-specific methodologies used to obtain patient population estimates and subpopulations
•Bibliography: complete bibliography of all sources analyzed for the methodology
•Key Sources: country-specific list of primary sources used to estimate key patient populations and subpopulations
18
Company Confidential
DECISION RESOURCES >
PatientBase™ – Application / Uses
> Estimate the number of people with drug-treatable disease or condition over time Percent diagnosed Percent treated
> Segment cases by age, gender, stage, severity, genetic factor, disease attribute, co-morbidity or country
> Annualized population forecasts> Compare populations across Indications
19
Company Confidential
DECISION RESOURCES >
Support & Services
> DR’s highly skilled Epidemiology staff will answer any questions regarding PatientBase™ Staff members with over 50 years combined work
experience
> DR’s Consulting Group along with Epidemiology staff can assist in any customized Epidemiology work Additional Indications Geography not covered in PatientBase™
20
Company Confidential
DECISION RESOURCES >
Oncology Indications in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.)
> Acute Myeloid Leukemia > Bladder Cancer-Superficial > Bladder Cancer-Metastatic > Bladder Cancer-Muscle-Invasive > Breast Cancer-Stage I > Breast Cancer-Stage II > Breast Cancer-Stage III > Breast Cancer-Stage IV > Cervical Cancer-Stage I > Cervical Cancer-Stage III > Cervical Cancer-Stage III > Cervical Cancer-Stage IV > Chronic Lymphocytic Leukemia-
High Risk
> Chronic Lymphocytic Leukemia-Intermed. Risk
> Chronic Lymphocytic Leukemia-Low Risk
> Chronic Myelogenous Leukemia > Colon Cancer-Stage I > Colon Cancer-Stage II > Colon Cancer-Stage III > Colon Cancer-Stage IV > Colorectal Cancer-Stage I > Colorectal Cancer-Stage II > Colorectal Cancer-Stage> Colorectal Cancer-Stage IV
AppendixAppendix
21
Company Confidential
DECISION RESOURCES >
Oncology Indications in PatientBase™ Cont.- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.)
> Esophageal Cancer - Distant > Esophageal Cancer - Limited > Esophageal Cancer - Regional > Esophageal Cancer - Unknown > Glioma > Liver Cancer - Distant > Liver Cancer - Limited > Liver Cancer - Regional > Liver Cancer - Unknown > Malignant Melanoma-Stage I > Malignant Melanoma-Stage II> Malignant Melanoma-Stage III > Malignant Melanoma-Stage IV
> Multiple Myeloma-Stage I > Multiple Myeloma-Stage II > Multiple Myeloma-Stage III> Non-Hodgkin's Lymphoma-Aggressive> Non-Hodgkin's Lymphoma-Indolent> Non-Small-Cell Lung Cancer-Stage I> Non-Small-Cell Lung Cancer-Stage II> Non-Small-Cell Lung Cancer-Stage III> Non-Small-Cell Lung Cancer-Stage IV> Ovarian Cancer-Stage I > Ovarian Cancer-Stage II> Ovarian Cancer-Stage III > Ovarian Cancer-Stage IV
AppendixAppendix
22
Company Confidential
DECISION RESOURCES >
Oncology Indications in PatientBase™ Cont.- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.)
> Pancreatic Cancer-Distant> Pancreatic Cancer-Localized> Pancreatic Cancer-Regional> Prostate Cancer-Stage I > Prostate Cancer-Stage II > Prostate Cancer-Stage III > Prostate Cancer-Stage IV > Rectal Cancer-Stage I > Rectal Cancer-Stage II > Rectal Cancer-Stage III > Rectal Cancer-Stage IV
> Renal Cell Carcinoma-Stage I/II > Renal Cell Carcinoma-Stage III > Renal Cell Carcinoma-Stage IV > Small-Cell Lung Cancer-Extensive > Small-Cell Lung Cancer-Limited > Stomach Cancer - Distant > Stomach Cancer - Limited> Stomach Cancer - Regional > Stomach Cancer - Unknown
AppendixAppendix
23
Company Confidential
DECISION RESOURCES >
Central Nervous System Indications in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.)
> Acute Ischemic Stroke> Alzheimer’s Disease > Attention-Deficit/Hyperactivity Disorder-
Adult > Attention-Deficit/Hyperactivity Disorder-
Pediatric > Bipolar Disorder > Chronic Low Back Pain> Dementia > Epilepsy> Generalized Anxiety Disorder > Insomnia > Major Depression > Migraine (Prophylaxis) > Mild Cognitive Impairment> Minor Depression> Multiple Sclerosis (Chronic-Progressive)
> Multiple Sclerosis (Relapsing-Remitting)> Narcolepsy > Obsessive-Compulsive Disorder> Obstructive Sleep Apnea> Osteoarthritic Pain> Panic Disorder > Parkinson’s Disease > Post-operative Pain> Restless Legs Syndrome> Rheumatoid Arthritic Pain > Schizophrenia > Social Anxiety Disorder> Postherpetic Neuralgia > Painful Diabetic Neuropathy> HIV-Related Neuropathic Pain
AppendixAppendix
24
Company Confidential
DECISION RESOURCES >
Infectious Diseases Indications in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.)
> Acute Exacerbations of Chronic Bronchitis > Community-Acquired Pneumonia > Hepatitis B > Hepatitis C> Herpes Zoster> HIV-Newly Diagnosed Population > Human Immunodeficiency Virus > Influenza A and B > Methicillin-Resistant Staph A > Sepsis > Complications of Soft Skin Tissue Infection
AppendixAppendix
25
Company Confidential
DECISION RESOURCES >
Cardiovascular Indications in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.)
> Acute Heart Failure> Acute Myocardial Infarction> Atrial Fibrillation > Chronic Heart Failure> Coronary Heart Disease > Dyslipidemia > Hypertension > Peripheral Arterial Disease > Post-Myocardial Infarction> Pulmonary Arterial Hypertension> Non-ST-Elevation Myocardial Infarction > Venous Thromboembolism
AppendixAppendix
26
Company Confidential
DECISION RESOURCES >
Immune and Inflammatory Disorders Indications in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.)
> Allergic Rhinitis > Asthma> Crohn’s Disease > Diabetic Nephropathy > Eczema/ Atopic Dermatitis> Metabolic Syndrome > Fibromyalgia > Osteoarthritis
AppendixAppendix
> Psoriasis> Rheumatoid Arthritis > Systemic Lupus Erythematosus> Type 1 Diabetes> Type 2 Diabetes > Ulcerative Colitis > Urticaria
27
Company Confidential
DECISION RESOURCES >
High-Interest Disease in PatientBase™- For U.S.A, Japan & Europe (France, Germany, Italy, Spain, U.K.)
> Age-Related Macular Degeneration (Wet)> Benign Prostatic Hyperplasia > Chronic Obstructive Pulmonary Disease> Diabetic Neuropathy > Diabetic Retinopathy> Erectile Dysfunction > Female Sexual Dysfunction> Gastroesophageal Reflux Disease> Irritable Bowel Syndrome > Obesity > Osteoporosis > Urinary Incontinence (Urge) > Urinary Incontinence (Stress)
AppendixAppendix
28
Company Confidential
DECISION RESOURCES >
For Further Information
North America
Mr. Bob FucileTel. 781-296-2500Fax [email protected] Resources, Inc.260 Charles StreetWaltham, MA 02453
Europe
Ms. Vera Bisegna
Tel. +32-2-351-10-79
Fax +32-2-351-23-47
Decision Resources International, Inc.
Avenue des Chasseurs, 1
1410 Waterloo, Belgium
Japan
Ms. Makiko YoshimotoTel. +81-3-5401-2615Fax [email protected] Resources International, Inc.Fukide Building F44-1-13 ToranomonMinato-ku, Tokyo 105-0001 Japan
